Somatostatin

New England Journal of Medicine

Volumn 309, Issue 25, 1983, Pages 1556-1563

  Reichlin, Seymour ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; NEUROTRANSMITTER; SOMATOSTATIN; THYROTROPIN;

DIGESTIVE SYSTEM; ENDOCRINE SYSTEM; HUMAN; NUTRIENT; REVIEW;

ANIMAL; BEHAVIOR; BRAIN CHEMISTRY; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL SYSTEM; GLUCAGON; HUMAN; INSULIN; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; NERVOUS SYSTEM; NERVOUS SYSTEM PHYSIOLOGY; NEUROSECRETORY SYSTEMS; SOMATOSTATIN;

EID: 0021019016     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198312223092506     Document Type: Review

References (57)

1. Patel YC, Amherdt M, Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets. Science 1982; 217: 1155–1156.
2. Krejs GJ, Orci L, Conlon JM, et al., Somatostatinoma syndrome: biochemical, morphologic and clinical features. N Engl J Med 1979; 301: 185–192.
3. Ricci GL, Fevery J. Cholestatic action of somatostatin in the rat: effect on the different fractions of bile secretion. Gastroenterology 1981; 81: 552–562.
4. Raptis S, Schlegel W, Pfeiffer EE. Effects of somatostatin on gut and pancreas. In: Bloom SR, ed. Gut hormones. Edinburgh: Churchill Living-stone, 1978:446–452.
5. Schusdziarra V, Zyznar E, Rouiller D, et al., Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science 1980; 207: 530–532.
6. Uvnäs-Wallensten K. Luminal secretion of gut peptides. Clin Gastroenterol 1980; 9: 545–553.
7. Thomas WEG. Somatostatin — the long lost antral chalone. Med Hypotheses 1980; 6: 919–927.
8. Schusdziarra V, Rouiller D, Unger RH. Oral administration of somatostatin reduces postprandial plasma triglycerides, gastrin and gut glucagonlike immunoreactivity. Life Sci 1979; 24: 1595–1600.
9. Dayal Y, O'Brian DS, Wolfe HJ. SRIF and G-cell hyperplasia in duodenal ulcer disease: a morphometric study. Lab Invest 1979; 40: 251. abstract.
10. Schonbrunn A, Tashjian AH Jr. Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 1978; 253: 6473–6483.
11. Schonbrunn A. Modulation of somatostatin receptors by thyrotropin-releasing hormone in a clonal pituitary cell strain. J Biol Chem 1980; 255: 190–198.
12. Srikant CB, Patel YC. Somatostatin analogs: dissociation of brain receptor binding affinities and pituitary actions in the rat. Endocrinology 1981; 108: 341–343.
13. Leitner JW, Rifkin RM, Maman A, Sussman KE. Somatostatin binding to pituitary plasma membranes. Biochem Biophys Res Commun 1979; 87: 919–927.
14. Srikant CB, Patel YC. Somatostatin receptors: identification and characterization in rat brain membranes. Proc Natl Acad Sci USA 1981; 78: 3930–3934.
15. Mehler PS, Sussman AL, Maman A, Leitner JW, Sussman KE. Role of insulin secretagogues in the regulation of somatostatin binding by isolated rat islets. J Clin Invest 1980; 66: 1334–1338.
16. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982; 110: 1147–1154.
17. Pace CS, Tarvin JT. Somatostatin: mechanism of action in pancreatic islet β-cells. Diabetes 1981; 30: 836–842.
18. Curry DL, Bennett LL. Does somatostatin inhibition of insulin secretion involve two mechanisms of action? Proc Natl Acad Sci USA 1976; 73: 248–251.
19. Iversen LL, Lee CM, Gilbert RF, Hunt S, Emson PC. Regulation of neuropeptide release. Proc R Soc Lond [Biol] 1980; 210: 91–111.
20. Maeda K, Frohman LA. Release of somatostatin and thyrotropin-releasing hormone from rat hypothalamic fragments in vitro. Endocrinology 1980; 106: 1837–1842.
21. Ojeda SR, Negro-Vilar A, Arimura A, McCann SM. On the hypothalamic mechanism by which prostaglandin E2 stimulates growth hormone release: in vivo and in vitro studies. Neuroendocrinology 1980; 31: 1–7.
22. Terry LC, Rorstad OP, Martin JB. The release of biologically and immunologically reactive somatostatin from perifused hypothalamic fragments. Endocrinology 1980; 107: 794–800.
23. Renaud LP. Electrophysiology of brain peptides. In: Gotto AM Jr., Peck EJ Jr., Boyd AE III, eds. Brain peptides: a new endocrinology. Amsterdam: Elsevier/North Holland, 1979:119–138.
24. Dichter MA, Delfs JR. Somatostatin and cortical neurons in cell culture. Adv Biochem Psychopharmacol 1981; 28: 145–157.
25. Havlicek V, Friesen HG. Comparison of behavioral effects of somatostatin and β-endorphin in animals. In: Collu R, Barbeau A, Ducharme JR, Rochefort J-G, eds. Central nervous system effects of hypothalamic hormones and other peptides. New York: Raven Press, 1979:381–402.
26. Chihara K, Arimura A, Chihara M, Schally AV. Effect of intraventricular administration of anti-somatostatin γ-globulin on the lethal dose-50 of strychnine and pentobarbital in rats. Endocrinology 1978; 103: 912–916.
27. Ioffe S, Havlicek V, Friesen H, Chernick V. Effect of somtostatin and L-glutamate on neurons of the sensorimotor cortex in awake habituated rabbits. Brain Res 1978; 153: 414–418.
28. Patel YC, Rao K, Reichlin S. Somatostatin in human cerebrospinal fluid. N Engl J Med 1977; 296: 529–533.
29. Rubinow DR, Gold PW, Post RM, et al., CSF somatostatin in affective illness. Arch Gen Psychiatry 1983; 40: 409–412.
30. Kronheim S, Berelowitz M, Pimstone B. The presence of immunoreactive growth hormone release-inhibiting hormone in normal cerebrospinal fluid. Clin Endocrinol (Oxf) 1977; 6: 411–415.
31. Wass JAH, Penman E, Medbak S, Rees LH, Besser GM. CSF and plasma somatostatin levels in acromegaly. Clin Endocrinol (Oxf) 1980; 13: 235–241.
32. Sørensen KV, Christensen SE, Dupont E, Hansen AP, Pedersen E, Ørskov H. Low somatostatin content in cerebrospinal fluid in multiple sclerosis: an indicator of disease activity? Acta Neurol Scand 1980; 61: 186–191.
33. Berelowitz M, Perlow MJ, Hoffman HJ, Frohman LA. The diurnal variation of immunoreactive thyrotropin-releasing hormone and somatostatin in the cerebrospinal fluid of the rhesus monkey. Endocrinology 1981; 109: 2102–2109.
34. Davies P, Katzman R, Terry RD. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980; 288: 279–280.
35. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 1980; 20: 373–377.
36. Cooper PE, Fernstrom MH, Rorstad OP, Leeman SE, Martin JB. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res 1981; 218: 219–232.
37. Hochman HI, Judge DM, Reichlin S. Precocious puberty and hypothalamic hamartoma. Pediatrics 1981; 67: 236–244.
38. Gemer RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238: 298–302.
39. Kayasseh L, Gyr K, Keller U, Stalder GA, Wall M. Somatostatin and cimetidine in peptic-ulcer haemorrhage: a randomised controlled trial. Lancet 1980; 1: 844–846.
40. Limberg B, Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med 1980; 303: 284.
41. Usadel K-H, Leuschner U, Überla KK. Treatment of acute pancreatitis with somatostatin: a multicenter double-blind trial. N Engl J Med 1980; 303: 999–1000.
42. Klempa I, Schwedes U, Encke A, Usadel K-H. Proceedings of the Second International Symposium on Somatostatin. Athens, Greece, June 1 to 3, 1981. Rome, Serono Symposia 1981. abstract.
43. Strada L, Vigo PL, DeRai P, Gredelli B, Cavagnini F. Treatment of pancreatic fistulas with somatostatin. In: Proceedings of the Second International Symposium on Somatostatin. Athens, Greece, June 1 to 3, 1981. Rome, Serono Symposia 1981. abstract.
44. Szabo S, Usadel KH. Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions. Experientia 1982; 38: 254–256.
45. Vinik AI, Shapiro B, Glaser B, Wagner L. Circulating somatostatin in primates. In: Bloom SR, Polak JM, eds. Gut hormones. 2nd ed. Edinburgh: Churchill Livingstone, 1981:371–375.
46. Kronheim S, Berelowitz M, Pimstone BL. The characterization of somatostatin-like immunoreactivity in human serum. Diabetes 1978; 27: 523–529.
47. Wright J, Abolfathi A, Penman E, Marks V. Pancreatic somatostatinoma presenting with hypoglycaemia. Clin Endocrinol (Oxf) 1980; 12: 603–609.
48. Mackes K, Itoh M, Greene K, Gerich J. Radioimmunoassay of human plasma somatostatin. Diabetes 1981; 30: 728–734.
49. Calmiche JP, Colin R, DuBois PM, et al., Calcitonin secretion by a pancreatic somatostatinoma. N Engl J Med 1978; 299: 1252.
50. Pipeleers D, Somers G, Gepts W, De Nutte N, De Vroede M. Plasma pancreatic hormone levels in a case of somatostatinoma: diagnostic and therapeutic implications. J Clin Endocrinol Metab 1979; 49: 572–579.
51. Hirsch HJ, Gabbay KH. Radioimmunoassay of somatostatin-like immunoreactivity in human plasma. Diabetes 1978; 27: 441. abstract.
52. Penman E, Wass JAH, Besser GM, Rees LH. Somatostatin secretion by lung and thymic tumours. Clin Endocrinol (Oxf) 1980; 13: 613–620.
53. Patel YC, Wheatley T, Fitz-Patrick D, Brock G. A sensitive radioimmunoassay for immunoreactive somatostatin in extracted plasma: measurement and characterization of portal and peripheral plasma in the rat. Endocrinology 1980; 107: 306–313.
54. Vale W, Rivier J, Ling N, Brown M. Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978; 27: Supplement 1: 1391–1401.
55. Murphy WA, Meyers CA, Coy DH. Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs. Endocrinology 1981; 109: 491–495.
56. Hirschmann R. Design, synthesis and biological evaluation of an orally active, long acting analog of somatostatin. In: Proceedings of the Second International Symposium on Somatostatin. Athens, Greece, June I to 3, 1981. Rome, Serono, Symposia 1981. abstract.
57. Veber DF, Holly FW, Nutt RF, et al., Highly active cyclic and bicyclic analogues of reduced ring size. Nature 1979; 280: 512–514.